Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hariharan Subramanian
Northwestern University, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
NanoCytomics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research is related to the focus of an entity in which Professor Subramanian has significant financial interests, NanoCytomics. NanoCytomics has licensed intellectual property arising from Northwestern research related to a technology platform within the field of nanocytology that is intended to identify patients that are likely to benefit from gold-standard cancer diagnostic procedures. Partial wave spectroscopic (PWS) microscopy is a breakthrough technology platform that enables quantification of the nanoscale architecture of the cell with unprecedented accuracy.
This research aims to refine PWS to give faster results and help identify patients that require diagnostic testing This work relates to intellectual property owned by NanoCytomics and new intellectual property arising from this research will likely utilize NanoCytomics as a commercial vehicle. Therefore, a potential conflict of interest exists regarding Professor Subramanian’s NanoCytomics interests and this research that should be managed.
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology
Prostate cancer is the leading cancer among U.S. men. The biggest limitation of current prostate cancer management that it is essentially impossible to accurately prognosticate which patients harbor aggressive cancers that progress into a metastatic disease and need treatment and which patients have non-aggressive indolent cancers that would not pose harm. Technology developed in the proposed project will address this issue by detecting alterations in nanoscale morphology of prostate epithelial cells that are highly predictive of the risk of progression.
Filed on August 31, 2015.
Tell us what you know about Hariharan Subramanian's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Hariharan Subramanian”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Hariharan Subramanian | Northwestern University | Conflict of Interest | NanoCytomics | $40,000 - $59,999 |
| Hariharan Subramanian | Northwestern University | Conflict of Interest | NanoCytomics LLC. | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.